BioCryst Pharmaceuticals (BCRX) and Qiagen (QGEN) Head-To-Head Review

BioCryst Pharmaceuticals (NASDAQ: BCRX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.


This table compares BioCryst Pharmaceuticals and Qiagen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -392.09% -114.36% -48.44%
Qiagen 3.79% 11.91% 6.13%

Analyst Recommendations

This is a summary of current recommendations and price targets for BioCryst Pharmaceuticals and Qiagen, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 2 5 0 2.71
Qiagen 0 3 4 0 2.57

BioCryst Pharmaceuticals presently has a consensus price target of $8.83, indicating a potential upside of 55.79%. Qiagen has a consensus price target of $38.50, indicating a potential upside of 2.97%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Qiagen.

Insider and Institutional Ownership

89.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 62.0% of Qiagen shares are held by institutional investors. 5.2% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Qiagen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioCryst Pharmaceuticals $25.19 million 22.24 -$65.78 million ($0.78) -7.27
Qiagen $1.42 billion 6.02 $40.39 million $1.27 29.44

Qiagen has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioCryst Pharmaceuticals has a beta of 2.73, meaning that its share price is 173% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.


Qiagen beats BioCryst Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply